GlassScriptPhysician profile
Frank Ruiz
NPI 1417967019
$4,690.71
in general payments reported to CMS, 2019-2025
34 companies · $1,067 in 2025
The $1,067 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $781 · 2020: $456 · 2021: $243 · 2022: $595 · 2023: $787 · 2024: $763 · 2025: $1,067.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,617.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,616.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $491.62 | 2019-2025 | Creon, Skyrizi, Rinvoq |
| Ironwood Pharmaceuticals, INC | $475.66 | 2019-2025 | Linzess |
| Madrigal Pharmaceuticals | $447.17 | 2024-2025 | Rezdiffra, Resmetirom |
| Medtronic, INC. | $274.67 | 2023-2025 | Interstim, Signia |
| Pfizer INC. | $266.09 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $258.94 | 2019-2025 | Eohilia, Entyvio, Gattex |
| E.R. Squibb & Sons, L.L.C. | $255.74 | 2022-2023 | Zeposia |
| Allergan, INC. | $216.61 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $198.65 | 2019-2025 | Ocaliva |
| Celgene Corporation | $189.08 | 2021-2024 | Zeposia |
| Lilly USA, LLC | $134.95 | 2024 | Omvoh |
| Boehringer Ingelheim Pharmaceuticals, INC. | $133.39 | 2021-2024 | Jardiance |
| Ardelyx, INC. | $129.88 | 2023-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $124.03 | 2019-2024 | Xifaxan, Plenvu, Trulance |
| Boston Scientific Corporation | $123.10 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $122.19 | 2022 | |
| Qol Medical, LLC | $120.52 | 2022-2025 | Sucraid |
| Shionogi INC | $108.88 | 2019 | |
| Phathom Pharmaceuticals, INC. | $91.76 | 2024-2025 | Voquezna |
| Vivus LLC | $88.28 | 2025 | Qsymia, Pancreaze |
| Braintree Laboratories, INC. | $75.43 | 2023-2024 | Suflave |
| Redhill Biopharma INC. | $57.80 | 2022-2023 | Movantik, Aemcolo, Talicia |
| Laborie Medical Technologies Corp. | $51.75 | 2024 | |
| Intra-Sana Laboratories | $45.76 | 2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Janssen Biotech, INC. | $43.94 | 2019-2025 | Simponi Aria, Simponi, Tremfya |
| Gilead Sciences, INC. | $26.33 | 2020-2025 | |
| Novo Nordisk INC | $21.25 | 2025 | Wegovy |
| Capsovision, INC. | $20.84 | 2024 | Capsocam Plus |
| Aimmune Therapeutics, INC. | $17.75 | 2025 | Zenpep |
| Merck Sharp & Dohme LLC | $17.68 | 2023 | Dificid |
| Regeneron Healthcare Solutions, INC. | $16.05 | 2024 | Dupixent |
| Micro-Tech Endoscopy USA, INC. | $15.93 | 2023 | Clips (Need Marketed Device Name), Dat Closure Device |
| Blueprint Medicines Corporation | $15.03 | 2024 | Ayvakit |
| Olympus America INC. | $13.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Ruiz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.